Huntington’s disease is the kind of diagnosis that rearranges a family’s calendar for decades — progressive, inherited, and still without an approved therapy that slows the biology itself. That’s why uniQure’s latest update on ifezuntirgene inilparvovec (AMT-130), a one-time gene therapy delivered into the striatum, lands with careful hope rather than fireworks.
The company reported additional Phase I/II data (cutoff June 30, 2026) while a Biologics License Application already sits with the FDA under the accelerated pathway. AMT-130 is the first investigational Huntington’s therapy to receive both Breakthrough Therapy and Regenerative Medicine Advanced Therapy (RMAT) designations from the FDA.
At 36 months — the regulatory anchor timepoint for the submitted BLA — an updated look at 15 high-dose patients showed about 80% slowing on the composite Unified Huntington’s Disease Rating Scale (cUHDRS; nominal p=0.005) and about 67% slowing on Total Functional Capacity (TFC; nominal p=0.011) versus a propensity-matched external control.
At 48 months (12 high-dose patients), TFC still showed about 61% slowing (nominal p=0.008), while cUHDRS slowing of about 44% missed statistical significance (p=0.144). uniQure notes substantial missing data and possible survivor bias in the updated natural-history controls may understate the treatment effect at four years; a post-hoc analysis using the prior control set looked stronger. Functional capacity — work, chores, self-care — is the measure that often matters most at the kitchen table, and seeing that signal hold is why clinicians quoted in the release sound measured but moved.
Safety remains generally manageable, with most common issues tied to the surgical delivery and previously disclosed inflammation events that resolved. This is still clinical-stage science under FDA review, not a cure in a bottle — and the company is clear these new topline numbers were not part of the already-submitted BLA.
Why it matters
Even if Huntington’s has never touched your family, disease-modifying gene therapy is a preview of how inherited brain diseases might be treated: one carefully aimed dose, years of follow-up, and endpoints that track real life. For the tens of thousands of people living with HD in the U.S., Europe, and UK — and the many more who carry the gene — every solid data update is a reason to keep watching the science without skipping the caveats.
What’s next
The BLA review continues under the accelerated framework built around the earlier 36-month package; these expanded analyses will feed scientific meetings and, potentially, the broader evidence story. A confirmatory study path and any FDA questions remain the practical next chapters. uniQure has archived an investor webcast and presentation from the Sept. 29, 2026 update for anyone who wants the charts straight from the source.
Sources: - https://www.biospace.com/press-releases/uniqure-announces-additional-data-from-ongoing-phase-i-ii-studies-of-ifezuntirgene-inilparvovec-amt-130-in-huntingtons-disease-showing-continued-slowing-of-disease-progression - https://www.uniqure.com/investors-media/events-presentations